Prostate cancer (PCa) is the second most common cause of cancer-related death in men in the United States. While multiple molecular events contribute to prostate cancer progression, it has become increasingly evident that epigenetic changes play pivotal roles in regulating cancer development. Polycomb repressive complex (PRC) members maintain the gene expression status of a cell by epigenetically modifying histone proteins. Histone methyltransferase EZH2, an oncogenic PRC2 member, initiates the transcriptional repression by trimethylating histone H3 at lysine 27. We have shown that EZH2 is overexpressed in aggressive prostate and breast cancers, predicts disease outcome, and is required for cancer cell survival. In addition, our studies have shown that EZH2 down-regulates multiple tumor suppressors and a genomic loss of microRNA-101 results in unregulated expression of EZH2 in aggressive tumors. While the role of EZH2 in regulating protein-coding genes is known, its role in regulating microRNA (miR) expression has not been studied. MiRs are critical regulators of cellular functions and are commonly altered in cancers including down regulation of several tumor suppressor miRs. Thus, we hypothesize that transcriptional repressor EZH2 plays a key role in regulating microRNA expression by epigenetic silencing and EZH2-regulated miRs play critical roles in PCa progression. Our preliminary data suggest that EZH2 down regulates multiple miRs, including miR-203 and the miR-200a, miR-200bc family. MiR-203 and mir-200a, bc in turn regulate PRC1 members, BMI1 and RING2. Thus the aims of this proposal are to extend these findings and gain further insights into the regulation of miRs by EZH2 and the role of these miRs in PCa development. In order to accomplish these goals, in Specific Aim 1, we will investigate the role of EZH2 in regulating miR expression in multiple cell types. We will first perform miR profiling using RNA from prostate cell lines in which EZH2 expression is modulated. We will validate the EZH2 regulated miR expression in prostate tumor tissues and correlate them with EZH2 expression.
In Specific Aim 2, we will investigate the role of EZH2-regulated miRs in PCa and their role in targeting the PRC1 members.
In Specific Aim 3, we will investigate the role of EZH2-regulated miRs in prostate tumorigenesis. We will use select EZH2-regulated miRs that are directly repressed by EZH2 and characterize the consequences of their modulation using both cell line and in vivo models of PCa. Relevance to Public Health: Successful completion of the proposed work will provide evidence for an intricate network of miR and epigenetic regulators in PCa development and identify potential diagnostic and prognostic markers, which in turn may improve PCa therapy through better diagnosis and disease monitoring. Our results may ultimately provide credence for therapeutic "re-introduction" of EZH2-repressed tumor suppressor miRs in cancer.
Prostate cancer is one of the most common causes of cancer related death of men in the United States, yet the etiology of this disease is relatively unknown and current therapies have a significant failure rate for advanced disease. Oncogenic histone methyltransferase EZH2 which is overexpressed in aggressive prostate cancer is known to play essential roles in aggressive prostate cancer and our preliminary studies have found that it regulates critical tumor suppressive microRNAs in prostate cancer cells. Our proposed investigations will provide evidence for the role of EZH2 in regulating critical tumor associated microRNAs, suggest biological role of EZH2 regulated microRNAs and will identify potential prostate cancer biomarkers and valuable therapeutic targets for prostate cancer.
|Chakravarthi, Balabhadrapatruni V S K; Nepal, Saroj; Varambally, Sooryanarayana (2016) Genomic and Epigenomic Alterations in Cancer. Am J Pathol 186:1724-35|
|Chakravarthi, B V S K; Goswami, M T; Pathi, S S et al. (2016) MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. Oncogene 35:6330-6340|
|Beltran, Himisha; Prandi, Davide; Mosquera, Juan Miguel et al. (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298-305|
|Goswami, Moloy T; Chen, Guoan; Chakravarthi, Balabhadrapatruni V S K et al. (2015) Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. Oncotarget 6:23445-61|
|Chakravarthi, Balabhadrapatruni V S K; Pathi, Satya Sreehari; Goswami, Moloy T et al. (2014) The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget 5:6654-69|
|Asangani, Irfan A; Ateeq, Bushra; Cao, Qi et al. (2013) Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell 49:80-93|
|Wang, Rui; Asangani, Irfan A; Chakravarthi, Balabhadrapatruni V S K et al. (2012) Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia 14:905-14|
|Cao, Qi; Mani, Ram-Shankar; Ateeq, Bushra et al. (2011) Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 20:187-99|